Maria Leonsson-Zachrisson
Overview
Explore the profile of Maria Leonsson-Zachrisson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
424
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bhattacharya C, Ericsson H, Johansson S, Parkinson J, Boca S, Yang Y, et al.
Br J Clin Pharmacol
. 2025 Feb;
PMID: 39962632
Aims: The aim of this phase 1 trial was to assess the pharmacokinetics, safety and tolerability of balcinrenone (previously AZD9977) in participants with severe renal impairment vs. those with normal...
2.
Lam C, Kober L, Kuwahara K, Lund L, Mark P, Mellbin L, et al.
Eur J Heart Fail
. 2024 May;
26(8):1727-1735.
PMID: 38783712
Aims: Many patients with heart failure (HF) have chronic kidney disease (CKD) and may not tolerate mineralocorticoid receptor antagonists. We investigated the efficacy and safety of the novel mineralocorticoid receptor...
3.
Steg P, Bhatt D, Simon T, Fox K, Mehta S, Harrington R, et al.
N Engl J Med
. 2019 Sep;
381(14):1309-1320.
PMID: 31475798
Background: Patients with stable coronary artery disease and diabetes mellitus who have not had a myocardial infarction or stroke are at high risk for cardiovascular events. Whether adding ticagrelor to...
4.
Heeney M, Abboud M, Amilon C, Andersson M, Githanga J, Inusa B, et al.
Contemp Clin Trials
. 2019 Aug;
85:105835.
PMID: 31446143
Background: An unmet need for therapies exists to reduce sickle cell disease (SCD) complications in pediatric patients. Activated platelets contribute to the formation of cellular aggregates during sickling and vaso-occlusive...
5.
Du X, Zheng Y, Yang P, Ma S, Yu Z, Su X, et al.
Adv Ther
. 2019 May;
36(7):1595-1605.
PMID: 31119693
Introduction: Ticagrelor is an oral, reversible, direct-acting P2Y receptor inhibitor approved for the prevention of cardiovascular events in acute coronary syndrome (ACS). In China, drug intensive monitoring regulations for new...
6.
Kanter J, Abboud M, Kaya B, Nduba V, Amilon C, Gottfridsson C, et al.
Br J Haematol
. 2018 Nov;
184(2):269-278.
PMID: 30443999
Ticagrelor is an antiplatelet agent for adults with coronary artery disease. The inhibition of platelet activation may decrease the frequency of vaso-occlusion crisis (VOC) in sickle cell disease (SCD). The...
7.
Gao R, Wu Y, Liu H, Su G, Yuan Z, Zhang A, et al.
Cardiovasc Drugs Ther
. 2018 Mar;
32(1):47-56.
PMID: 29488142
Purpose: Ticagrelor is an orally administered, reversibly binding, direct-acting P2Y receptor antagonist previously evaluated in several phase III trials. This phase IV, multicenter, single-arm trial assessed the safety and incidence...
8.
Bergthorsdottir R, Ragnarsson O, Skrtic S, Glad C, Nilsson S, Ross I, et al.
J Clin Endocrinol Metab
. 2017 Sep;
102(11):4264-4272.
PMID: 28945861
Context: Patients with Addison's disease (AD) have increased cardiovascular mortality. Objective: To study visceral fat and conventional and exploratory cardiovascular risk factors in patients with AD. Design: A cross-sectional, single-center,...
9.
Johansson S, Knutsson M, Leonsson-Zachrisson M, Rosenbaum D
Clin Pharmacol Drug Dev
. 2017 Mar;
6(5):457-465.
PMID: 28339149
Tenapanor (RDX5791/AZD1722) is a minimally systemic small-molecule inhibitor of the sodium/hydrogen exchanger NHE3. Tenapanor acts in the gut to reduce absorption of sodium and phosphate. This phase 1 open-label, 3-way...
10.
Block G, Rosenbaum D, Leonsson-Zachrisson M, Astrand M, Johansson S, Knutsson M, et al.
J Am Soc Nephrol
. 2017 Feb;
28(6):1933-1942.
PMID: 28159782
Hyperphosphatemia is common among patients with CKD stage 5D and is associated with morbidity and mortality. Current guidelines recommend lowering serum phosphate concentrations toward normal. Tenapanor is a minimally absorbed...